Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U2JP
|
||||
| Former ID |
DAP000639
|
||||
| Drug Name |
Sitagliptin
|
||||
| Synonyms |
Janumet; Januvia; Sitagliptan; Xelevia; Sitagliptin phosphate; Januvia (TN); MK-0431; Sitagliptin (Prop.INN); Januvia (merck & Co.); (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Hypoglycemic Agents
|
||||
| Company |
Merck & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H15F6N5O
|
||||
| InChI |
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
|
||||
| InChIKey |
MFFMDFFZMYYVKS-SECBINFHSA-N
|
||||
| CAS Number |
CAS 486460-32-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7885474, 9656038, 14904024, 16466401, 35668584, 46393524, 46505822, 46511716, 46513917, 46530623, 48034814, 50070925, 56365842, 78231257, 85789641, 92307950, 96025201, 99443685, 103502876, 112947540, 117695427, 126669712, 126731480, 134337929, 135206675, 136339733, 137005783, 143037551, 143497677, 152028143, 152164204, 152164205, 152238548, 152344340, 160646743, 160964592, 162201432, 164784279, 164824529, 164846813, 165235282, 165245552, 165702336, 170499559, 174006349, 174529510, 175268642, 178102906, 179231014, 186005103
|
||||
| ChEBI ID |
ChEBI:40237
|
||||
| SuperDrug ATC ID |
A10BH01
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | Inhibitor | [535810], [535813], [537022], [537506] | |
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| Ref 528715 | 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. | ||||
| Ref 538583 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022044. | ||||
| Ref 541437 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286). | ||||
| Ref 535810 | Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5;267(7):4824-33. | ||||
| Ref 535813 | Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481-6. | ||||
| Ref 537022 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
| Ref 537506 | Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Jun 21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.